

# Mark Pimentel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2691286/publications.pdf>

Version: 2024-02-01

261  
papers

11,458  
citations

29994

54  
h-index

31759

101  
g-index

271  
all docs

271  
docs citations

271  
times ranked

6194  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes. <i>Digestive Diseases and Sciences</i> , 2022, 67, 224-232.	1.1	23
2	Ultraviolet-A light increases mitochondrial anti-viral signaling protein in confluent human tracheal cells via cell-cell signaling. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2022, 226, 112357.	1.7	1
3	A Single Fasting Exhaled Methane Level Correlates With Fecal Methanogen Load, Clinical Symptoms and Accurately Detects Intestinal Methanogen Overgrowth. <i>American Journal of Gastroenterology</i> , 2022, 117, 470-477.	0.2	14
4	Duodenal microbiome changes in postmenopausal women: effects of hormone therapy and implications for cardiovascular risk. <i>Menopause</i> , 2022, 29, 264-275.	0.8	9
5	<i>Campylobacter</i> infection and the link with Irritable Bowel Syndrome: on the pathway towards a causal association. <i>Pathogens and Disease</i> , 2022, 80, .	0.8	5
6	A Smartphone Application Using Artificial Intelligence Is Superior To Subject Self-Reporting When Assessing Stool Form. <i>American Journal of Gastroenterology</i> , 2022, 117, 1118-1124.	0.2	7
7	Smoking has disruptive effects on the small bowel luminal microbiome. <i>Scientific Reports</i> , 2022, 12, 6231.	1.6	11
8	Small Intestine Bacterial Overgrowth Can Form an Indigenous Proinflammatory Environment in the Duodenum: A Prospective Study. <i>Microorganisms</i> , 2022, 10, 960.	1.6	5
9	High Prevalence of Small Intestinal Bacterial Overgrowth among Functional Dyspepsia Patients. <i>Digestive Diseases</i> , 2021, 39, 382-390.	0.8	14
10	Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts. <i>Clinical Rheumatology</i> , 2021, 40, 2277-2284.	1.0	11
11	Irritable Bowel Syndrome in Pregnancy. <i>American Journal of Gastroenterology</i> , 2021, 116, 480-490.	0.2	9
12	Endotracheal Application of Ultraviolet-A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus-2: A First-in-Human Study. <i>Advances in Therapy</i> , 2021, 38, 4556-4568.	1.3	8
13	Ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with Coronavirus. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 35, 102457.	1.3	2
14	Age and the aging process significantly alter the small bowel microbiome. <i>Cell Reports</i> , 2021, 36, 109765.	2.9	67
15	ACG Clinical Guideline: Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 17-44.	0.2	341
16	Quantitative sequencing clarifies the role of disruptor taxa, oral microbiota, and strict anaerobes in the human small-intestine microbiome. <i>Microbiome</i> , 2021, 9, 214.	4.9	31
17	Breath Test Gas Patterns in Inflammatory Bowel Disease with Concomitant Irritable Bowel Syndrome-Like Symptoms: A Controlled Large-Scale Database Linkage Analysis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2388-2396.	1.1	12
18	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , 2020, 159, 1526-1532.	0.6	84

#	ARTICLE	IF	CITATIONS
19	Ultraviolet A light effectively reduces bacteria and viruses including coronavirus. PLoS ONE, 2020, 15, e0236199.	1.1	40
20	Gut Microbiota Dysbiosis in Functional Dyspepsia. Microorganisms, 2020, 8, 691.	1.6	36
21	Acute appendicitis is associated with appendiceal microbiome changes including elevated <i>Campylobacter jejuni</i> levels. BMJ Open Gastroenterology, 2020, 7, e000412.	1.1	16
22	Mapping the Segmental Microbiomes in the Human Small Bowel in Comparison with Stool: A REIMAGINE Study. Digestive Diseases and Sciences, 2020, 65, 2595-2604.	1.1	65
23	The duodenal microbiome is altered in small intestinal bacterial overgrowth. PLoS ONE, 2020, 15, e0234906.	1.1	68
24	Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. Frontiers in Psychiatry, 2020, 11, 664.	1.3	82
25	Comparing the rates of methane production in patients with and without appendectomy: results from a large-scale cohort. Scientific Reports, 2020, 10, 867.	1.6	8
26	ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology, 2020, 115, 165-178.	0.2	224
27	Microbiome and Its Role in Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2020, 65, 829-839.	1.1	111
28	Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. Clinical and Translational Gastroenterology, 2020, 11, e00144.	1.3	12
29	Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome. Neurogastroenterology and Motility, 2020, 32, e13875.	1.6	11
30	Sa1912 – Revealing the Entire Intestinal Microbiota and Its Associations to the Genetic, Immunologic, and Neuroendocrine Ecosystems: Methodology for the Reimagine Study. Gastroenterology, 2019, 156, S-450.	0.6	1
31	Su1949 – Small Intestinal Aspirates Require Specific Treatment to Optimize Microbial Analysis: Validation of a Novel Technique from the Reimagine Study. Gastroenterology, 2019, 156, S-670.	0.6	1
32	Optimizing microbiome sequencing for small intestinal aspirates: validation of novel techniques through the REIMAGINE study. BMC Microbiology, 2019, 19, 239.	1.3	28
33	Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. Digestive Diseases and Sciences, 2019, 64, 3115-3121.	1.1	24
34	An Approach to the Patient With Chronic Undiagnosed Abdominal Pain. American Journal of Gastroenterology, 2019, 114, 726-732.	0.2	21
35	Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea. American Journal of Gastroenterology, 2019, 114, 1886-1893.	0.2	45
36	Declining Rates of Referral for Irritable Bowel Syndrome Without Constipation at a Tertiary Care Center. Digestive Diseases and Sciences, 2019, 64, 182-188.	1.1	1

#	ARTICLE	IF	CITATIONS
37	Influence of Dietary Restriction on Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2019, 114, 212-220.	0.2	15
38	Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome. <i>Gut Microbes</i> , 2019, 10, 22-33.	4.3	57
39	Dyssynergic Defecation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1065-1073.	0.9	23
40	Fecal Incontinence in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1280-1290.	0.9	34
41	Small Intestinal Bacterial Overgrowth. , 2018, , 333-342.		0
42	Phenotype and Antibiotic Response in Patients With Flat Line Breath Test Results: A Large Scale Database Analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, S261.	0.2	1
43	Sa1219 - Validation of a 4-Gas Device for Breath Testing in the Determination of Small Intestinal Bacterial Overgrowth. <i>Gastroenterology</i> , 2018, 154, S-281.	0.6	2
44	Unique Differences in Breath Test Gas Patterns in Inflammatory Bowel Disease (IBD) Compared to Non-IBD Patients: A Large-Scale Database Linkage Analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, S381-S382.	0.2	1
45	Lactulose Breath Testing Predicts Response to Rifaximin for Cardinal Irritable Bowel Syndrome With Diarrhea (IBS-D). <i>American Journal of Gastroenterology</i> , 2018, 113, S270.	0.2	0
46	Evidence-based management of irritable bowel syndrome with diarrhea. <i>American Journal of Managed Care</i> , 2018, 24, S35-S46.	0.8	16
47	Examination of the effects of breath hydrogen and methane levels on the EC/IR II. <i>Journal of the Canadian Society of Forensic Science</i> , 2017, 50, 125-130.	0.7	0
48	Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1480-1485.	1.1	35
49	Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2455-2463.	1.1	43
50	Measurement of Hydrogen Sulfide during Breath Testing Correlates to Patient Symptoms. <i>Gastroenterology</i> , 2017, 152, S205-S206.	0.6	4
51	Autoimmunity as a Potential Cause of Post-Infectious Gut Dysmotility: A Longitudinal Observation. <i>American Journal of Gastroenterology</i> , 2017, 112, 656-657.	0.2	2
52	Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. <i>American Journal of Gastroenterology</i> , 2017, 112, 775-784.	0.2	525
53	Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 689-699.	1.4	18
54	Sustained Response and Predictors of Sustained Response in Patients who Respond to Multiple Courses of Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 152, S918.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Safety and Tolerability of High-Resolution Esophageal Manometry: A Large Database Analysis. <i>Gastroenterology</i> , 2017, 152, S325.	0.6	2
56	Declining Rates of Referral to Tertiary Care Center for IBS-D. <i>Gastroenterology</i> , 2017, 152, S720.	0.6	0
57	Cytotoxic Distending Toxin B (CdtB) Exposure Alone is Sufficient to Precipitate Autoimmunity and Changes to the Small Intestinal Microbiome in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2017, 152, S621.	0.6	1
58	Is small intestinal bacterial overgrowth involved in the pathogenesis of functional dyspepsia?. <i>Medical Hypotheses</i> , 2017, 106, 26-32.	0.8	23
59	Characterization of Abdominal Pain Response in Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Rifaximin. <i>Gastroenterology</i> , 2017, 152, S915.	0.6	0
60	Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	14
61	Responders Analysis in Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Rifaximin. <i>American Journal of Gastroenterology</i> , 2017, 112, S236.	0.2	0
62	Biomarkers of Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 20-26.	0.8	43
63	Lactulose Breath Testing Predicts the Response to Rifaximin. <i>American Journal of Gastroenterology</i> , 2017, 112, S227.	0.2	1
64	Assessing the Efficacy of Rifaximin in Diarrhea-Predominant Irritable Syndrome (IBS-D): A Post hoc Analysis of 2 Phase 3, Randomized, Placebo-Controlled Trials. <i>American Journal of Gastroenterology</i> , 2017, 112, S254.	0.2	0
65	SYN-010 Modified-Release Lovastatin Does Not Significantly Alter Lipid Parameters at Doses that Reduce Methane and Alleviate Symptoms in Patients Suffering Irritable Bowel Syndrome with Constipation (IBS-C). <i>American Journal of Gastroenterology</i> , 2016, 111, S256-S257.	0.2	1
66	Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway. <i>F1000Research</i> , 2016, 5, 606.	0.8	20
67	Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity. <i>Obesity</i> , 2016, 24, 576-582.	1.5	26
68	1134 The Utility of Measuring Anti-Cytotoxic Distending Toxin B and Anti-Vinculin Antibodies in a Tertiary Care Motility Practice: A Free Range Experience. <i>Gastroenterology</i> , 2016, 150, S230.	0.6	0
69	Tu1804 Anti-Vinculin and Anti-CdtB Antibodies in Mexican Subjects: A Case Control Study. <i>Gastroenterology</i> , 2016, 150, S952.	0.6	2
70	Su1210 SYN-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, Lowered Breath Methane and Improved Stool Frequency in Patients With IBS-C: Results of a Multi-Center Randomized Double-Blind Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2016, 150, S496-S497.	0.6	8
71	257 Assessment of Anti-Vinculin and Anti-CdtB Antibodies in IBS Subtypes. <i>Gastroenterology</i> , 2016, 150, S62.	0.6	0
72	450 Hydrogen- and Methane- Based Breath Testing (BT) in Gastrointestinal (GI) Disorders: Report of the North American Consensus Meeting. <i>Gastroenterology</i> , 2016, 150, S97.	0.6	4

#	ARTICLE	IF	CITATIONS
73	Small intestinal bacterial overgrowth is associated with irritable bowel syndrome and is independent of proton pump inhibitor usage. <i>BMC Gastroenterology</i> , 2016, 16, 67.	0.8	37
74	A definitive blood test for post-infectious irritable bowel syndrome?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1197-1199.	1.4	3
75	Intestinal methane production is associated with decreased weight loss following bariatric surgery. <i>Obesity Research and Clinical Practice</i> , 2016, 10, 728-733.	0.8	12
76	Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 37-49.	1.9	61
77	Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2016, 151, 1113-1121.	0.6	209
78	A Predictive Model to Estimate Cost Savings of a Novel Diagnostic Blood Panel for Diagnosis of Diarrhea-predominant Irritable Bowel Syndrome. <i>Clinical Therapeutics</i> , 2016, 38, 1638-1652.e9.	1.1	8
79	Autoimmunity and Irritable Bowel Syndrome: New Pathophysiology. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2016, 3, 41-45.	0.7	0
80	Mo1311 Evaluating the Safety and Efficacy of Eluxadoline for Treating Diarrhea-Predominant Irritable Bowel Syndrome: A Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S694.	0.6	0
81	Mo1314 Effect of Rifaximin Treatment on Anti-Vinculin Antibodies in IBS With Diarrhea. <i>Gastroenterology</i> , 2016, 150, S695.	0.6	1
82	Mo1641 Efficacy and Tolerability of Linaclotide and Plecanatide in Treating Irritable Bowel Syndrome With Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC): A Meta-Analysis. <i>Gastroenterology</i> , 2016, 150, S739.	0.6	16
83	Tu1750 Gastrointestinal (GI) Symptoms Associated With Excessive Intestinal Methane Production in the Pediatric Population: A Large Database Analysis. <i>Gastroenterology</i> , 2016, 150, S933-S934.	0.6	0
84	Reply. <i>Gastroenterology</i> , 2016, 150, 278-279.	0.6	2
85	Mo1319 Syn-010, a Proprietary Modified-Release Formulation of Lovastatin Lactone, May Improve Constipation by Inhibiting Enzymes in the Archaeal Methanogenesis Pathway: Results of Computational M. <i>Smithii</i> Enzyme-Ligand Docking Experiments. <i>Gastroenterology</i> , 2016, 150, S696-S697.	0.6	0
86	Understanding Breath Tests for Small Intestinal Bacterial Overgrowth. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1362-1363.	2.4	5
87	Su1793 Breath Methane and Hydrogen Composition in Inflammatory Bowel Disease (IBD) Is Strikingly Different From Non-IBD Patients and Is Associated With IBD-Associated Genes: A Large-Scale Database Linkage Analysis. <i>Gastroenterology</i> , 2016, 150, S553.	0.6	0
88	How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach. <i>Current Gastroenterology Reports</i> , 2016, 18, 8.	1.1	113
89	Breath Testing for Small Intestinal Bacterial Overgrowth: Should We Bother?. <i>American Journal of Gastroenterology</i> , 2016, 111, 307-308.	0.2	24
90	Improvements over Time in Individual Diarrhea-Predominant Irritable Bowel Syndrome Symptoms (IBS-D) with Rifaximin Repeat Treatment. <i>American Journal of Gastroenterology</i> , 2016, 111, S240.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Safety and Tolerability of Rifaximin in the Treatment of Irritable Bowel Syndrome (IBS): A Pooled Analysis of 4 Randomized, Placebo-Controlled Trials. <i>American Journal of Gastroenterology</i> , 2016, 111, S253.	0.2	0
92	Development and Seroconversion of Anti-Cytolethal Distending Toxin (CdtB) and Anti-Vinculin Antibodies in a Patient with Evolving Post-infectious IBS. <i>American Journal of Gastroenterology</i> , 2016, 111, S807.	0.2	0
93	Efficacy of Rifaximin on Bowel Movement Urgency in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): A Pooled Analysis of 3 Phase 3 Trials. <i>American Journal of Gastroenterology</i> , 2016, 111, S253-S254.	0.2	0
94	Does Bacterial Overgrowth Affect Breath Alcohol Levels on DUI Testing?: 2016 ACG Presidential Poster Award. <i>American Journal of Gastroenterology</i> , 2016, 111, S467.	0.2	0
95	Update on Irritable Bowel Syndrome Diagnostics and Therapeutics. <i>Gastroenterology and Hepatology</i> , 2016, 12, 442-5.	0.2	0
96	Rifaximin Repeat Treatment in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Produced No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. <i>American Journal of Gastroenterology</i> , 2015, 110, S761.	0.2	2
97	Lovastatin Lactone Inhibits Methane Production in Human Stool Homogenates. <i>American Journal of Gastroenterology</i> , 2015, 110, S753.	0.2	8
98	Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following <i>Campylobacter jejuni</i> Infection in a Rat Model. <i>Digestive Diseases and Sciences</i> , 2015, 60, 1195-1205.	1.1	70
99	Mo1865 Prevalence of Excessive Intestinal Methane Production and Its Variability With Age and Gender: A Large-Scale Database Analysis. <i>Gastroenterology</i> , 2015, 148, S-729-S-730.	0.6	4
100	Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1076-1087.	0.6	85
101	Small Intestinal Bacterial Overgrowth. , 2015, , 125-136.		1
102	Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects. <i>PLoS ONE</i> , 2015, 10, e0126438.	1.1	114
103	The Prevalence of Irritable Bowel Syndrome in Patients With Typical Symptoms Referred to the Gastroenterologist: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2015, 110, S758.	0.2	3
104	Accurate Identification of Excessive Methane Gas Producers by a Single Fasting Measurement of Exhaled Methane: A Large-scale Database Analysis ACG Category Award. <i>American Journal of Gastroenterology</i> , 2015, 110, S759-S760.	0.2	12
105	Breath Testing for Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Metaanalysis. <i>American Journal of Gastroenterology</i> , 2015, 110, S762-S763.	0.2	6
106	â€œStack of Coinsâ€œ on Manometry: Type 3 Achalasia Complicated by Severe Esophageal Diverticulosis. <i>American Journal of Gastroenterology</i> , 2015, 110, S269-S270.	0.2	0
107	Antibiotic Susceptibility of Skin Swab <i>Staphylococcus</i> Isolates From Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Treated With Repeat Courses of Rifaximin Showed No Evidence of Resistance. <i>American Journal of Gastroenterology</i> , 2015, 110, S751.	0.2	0
108	Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome. <i>Annals of Gastroenterology</i> , 2015, 28, 87-93.	0.4	10

#	ARTICLE	IF	CITATIONS
109	Methanogens, Methane and Gastrointestinal Motility. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 31-40.	0.8	183
110	Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 163-170.	0.8	42
111	Gastroesophageal Reflux Reported on Esophagram Does Not Correlate with pH Monitoring and High-resolution Esophageal Manometry. <i>American Surgeon</i> , 2014, 80, 1026-1029.	0.4	5
112	Adverse events appear to unblind clinical trials in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2014, 26, 482-488.	1.6	19
113	Probiotics for Antibiotic-Associated Diarrhea: PLACIDE Swings the Pendulum. <i>Gastroenterology</i> , 2014, 146, 1822-1823.	0.6	4
114	In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 236-241.	1.1	41
115	Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 973-983.	1.9	12
116	Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2014, 59, 1278-1285.	1.1	103
117	The Effect of Dried Plum on Targeted Gut Flora and Host Gene Expression in a Rat Model of Post-infectious IBS. <i>American Journal of Gastroenterology</i> , 2014, 109, S537.	0.2	0
118	Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. <i>BMC Gastroenterology</i> , 2013, 13, 46.	0.8	57
119	The Effect of Rifaximin on Gut Flora and Staphylococcus Resistance. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1676-1682.	1.1	35
120	Pathogen-Specific Risk of Celiac Disease Following Bacterial Causes of Foodborne Illness: A Retrospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3242-3245.	1.1	50
121	Tu2030 Quantitation of Bacteria in Duodenal Aspirates by qPCR Appears to Identify Viable Organisms in IBS. <i>Gastroenterology</i> , 2013, 144, S-908.	0.6	2
122	Tu2110 Circulating Antibodies to Cytolethal Distending Toxin B Correlate With the Development of Small Intestinal Bacterial Overgrowth in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2013, 144, S-931-S-932.	0.6	8
123	Gas and the Microbiome. <i>Current Gastroenterology Reports</i> , 2013, 15, 356.	1.1	74
124	Tu2029 Deep Sequencing Reveals That the Microbiome of the Human Duodenum Is Unique and Unrelated to Stool Bacterial Profiling. <i>Gastroenterology</i> , 2013, 144, S-908.	0.6	2
125	Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 223-231.	1.1	141
126	Measuring response in the gastrointestinal tract in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 700-706.	2.0	57



#	ARTICLE	IF	CITATIONS
127	Effect of repeated <i>Campylobacter jejuni</i> infection on gut flora and mucosal defense in a rat model of post infectious functional and microbial bowel changes. <i>Neurogastroenterology and Motility</i> , 2013, 25, 529.	1.6	26
128	Intestinal <i>Methanobrevibacter smithii</i> but not total bacteria is related to diet-induced weight gain in rats. <i>Obesity</i> , 2013, 21, 748-754.	1.5	53
129	Recorded Lower Esophageal Pressures as a Function of Electronic Sleeve Placement and Location of Gastric Pressure Measurement in Patients With Hiatal Hernia. <i>Journal of Neurogastroenterology and Motility</i> , 2013, 19, 479-484.	0.8	1
130	Anti-vinculin Antibodies: Multicenter Validation of a Diagnostic Blood Test for Irritable Bowel Syndrome: ACG Governors Award for Excellence in Clinical Research. <i>American Journal of Gastroenterology</i> , 2013, 108, S571.	0.2	1
131	Rifaximin and Neomycin in the Treatment of Constipation IBS with Methane as a Biomarker on Breath Testing: Presidential Poster. <i>American Journal of Gastroenterology</i> , 2013, 108, S563.	0.2	2
132	Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel disease. <i>Gastroenterology and Hepatology</i> , 2013, 9, 505-11.	0.2	9
133	Methanogens in Human Health and Disease. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012, 1, 28-33.	0.7	64
134	Pre-cebo. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 686-690.	1.1	14
135	<i>Methanobrevibacter smithii</i> Is the Predominant Methanogen in Patients with Constipation-Predominant IBS and Methane on Breath. <i>Digestive Diseases and Sciences</i> , 2012, 57, 3213-3218.	1.1	127
136	Visceroptosis of the bowel in the hypermobility type of Ehlers-Danlos syndrome: Presentation of a rare manifestation and review of the literature. <i>European Journal of Medical Genetics</i> , 2012, 55, 548-551.	0.7	36
137	Severity of Dyspeptic Symptoms Correlates with Delayed and Early Variables of Gastric Emptying. <i>Digestive Diseases and Sciences</i> , 2012, 58, 478-87.	1.1	20
138	Evaluation of Harm in the Pharmacotherapy of Irritable Bowel Syndrome. <i>American Journal of Medicine</i> , 2012, 125, 381-393.	0.6	68
139	Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2012, 12, 55.	0.8	59
140	Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence. <i>Current Gastroenterology Reports</i> , 2012, 14, 439-445.	1.1	37
141	Estimating the Contribution of Acute Gastroenteritis to the Overall Prevalence of Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2012, 18, 200-204.	0.8	38
142	Role of Cytolethal Distending Toxin in Altered Stool Form and Bowel Phenotypes in a Rat Model of Post-infectious Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2012, 18, 434-442.	0.8	53
143	The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1321-1329.	1.1	159
144	Rectal Hypersensitivity in Patients with Irritable Bowel Syndrome Compared to Healthy Control: A Systemic Review of Literature. <i>American Journal of Gastroenterology</i> , 2012, 107, S714.	0.2	1

#	ARTICLE	IF	CITATIONS
145	Rise in Hydrogen Production During Lactulose Breath Test Does Not Represent Oro-Cecal Transit Due to Lag in Peak Fermentation. <i>American Journal of Gastroenterology</i> , 2012, 107, S716.	0.2	1
146	Gender of Gastroenterologist and Years in Practice are Important in Drug Selection for D-IBS. <i>American Journal of Gastroenterology</i> , 2012, 107, S715.	0.2	0
147	Responsiveness of a Tri-Component Endpoint in Non-Constipation Irritable Bowel Syndrome: Pooled Results from Two Phase 3 Trials, TARGET 1 and TARGET 2. <i>American Journal of Gastroenterology</i> , 2012, 107, S712.	0.2	0
148	The Effect of Rifaximin on Staphylococcus Species in the Stool. <i>American Journal of Gastroenterology</i> , 2012, 107, S228.	0.2	0
149	Diagnosis of Pellagra Should Be Considered in Patients Suspicious for Crohn's. <i>American Journal of Gastroenterology</i> , 2012, 107, S379.	0.2	0
150	Intestinal methane production in obese individuals is associated with a higher body mass index. <i>Gastroenterology and Hepatology</i> , 2012, 8, 22-8.	0.2	33
151	Antibodies to Campylobacter Jejuni Cytolethal Distending Toxin Subunit B (CDT-B) Bind Enteric Neural Elements in Uninfected Mice Suggesting Molecular Mimicry. <i>Gastroenterology</i> , 2011, 140, S-521.	0.6	0
152	Antibodies to an 18-Residue Peptide of Cdt Are Found in the Serum of Rats in a Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2011, 140, S-371.	0.6	0
153	Healthy Controls Are Not Appropriately Identified for Comparison to Irritable Bowel Syndrome in Case Control Studies. <i>Gastroenterology</i> , 2011, 140, S-799.	0.6	1
154	Expression of B-Defensin-2 and Other PRO-Inflammatory Mediators Notable in IBS Are Increased in Rat Mucosa During Acute Campylobacter Jejuni Infection. <i>Gastroenterology</i> , 2011, 140, S-602.	0.6	0
155	Validating a New Genomic Test for Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2011, 140, S-798.	0.6	0
156	Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. <i>New England Journal of Medicine</i> , 2011, 364, 22-32.	13.9	880
157	Small Bowel Culture Confirms the Presence of Small Intestinal Bacterial Overgrowth in a Subset of IBS Subjects. <i>Gastroenterology</i> , 2011, 140, S-152.	0.6	6
158	Methane-Producing Subjects Have Higher Serum Glucose Levels During Oral Glucose Challenge Than Non-Methane Producers. <i>Gastroenterology</i> , 2011, 140, S-193.	0.6	1
159	Lymphocytic Esophagitis is Uncommon in Adult Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2011, 140, S-228.	0.6	1
160	Time to Onset and Durability of Relief in Non-Constipation IBS Patients Over 12 Weeks Following a 2-Week Course of Rifaximin. <i>Gastroenterology</i> , 2011, 140, S-605.	0.6	1
161	Inflammation and Microflora. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 69-85.	1.0	27
162	Dietary Fat Content Influences the Natural Colonization of Sprague-Dawley Rats With Methanobrevibacter Smithii. <i>Gastroenterology</i> , 2011, 140, S-333.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Repeat Exposure to C. Jejuni Increases the Development of SIBO in a Rat Model of Post-Infectious IBS. <i>Gastroenterology</i> , 2011, 140, S-602-S-603.	0.6	0
164	Concomitant Methane and Hydrogen Production in Humans is Associated With a Higher Body Mass Index. <i>Gastroenterology</i> , 2011, 140, S-335.	0.6	3
165	Daily Variation of Bowel Habits Predicts a Diagnosis of IBS Among Patients Referred to a General Gastroenterologist for Evaluation of Chronic Diarrhea: Validation of the LA/IBS Diagnostic Strategy. <i>Gastroenterology</i> , 2011, 140, S-800.	0.6	1
166	Importance of Diarrhea in Evaluating Constipation in Irritable Bowel Syndrome Clinical Studies. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 790-793.	1.1	3
167	Factor Analysis Demonstrates a Symptom Cluster Related to Methane and Non-methane Production in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 40-44.	1.1	12
168	History of Tonsillectomy Is Associated With Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 912.	1.1	11
169	Apple Sauce Improves Detection of Esophageal Motor Dysfunction During High-Resolution Manometry Evaluation of Dysphagia. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1723-1728.	1.1	30
170	Antibiotic Prophylaxis Prevents the Development of a Post-Infectious Phenotype in a New Rat Model of Post-Infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1962-1966.	1.1	15
171	Relationships Among the Lactulose Breath Test, Intestinal Gas Volume, and Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2059-2066.	1.1	13
172	Methane on Breath Testing Is Associated with Constipation: A Systematic Review and Meta-analysis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1612-1618.	1.1	151
173	Acute and Chronic Histological Changes of the Small Bowel Secondary to C. jejuni Infection in a Rat Model for Post-Infectious IBS. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2575-2584.	1.1	29
174	Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2067-2072.	1.1	86
175	Serum sTREM-1 as a Surrogate Marker of Treatment Outcome in Patients with Peptic Ulcer Disease. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3590-3595.	1.1	8
176	Pathogen-specific Risk of Functional Gastrointestinal Disorders, Gastroesophageal Reflux Disease and Celiac Disease Following Acute Enteric Infection. <i>American Journal of Gastroenterology</i> , 2011, 106, S512.	0.2	1
177	Understanding Harm in the Pharmacotherapy of Irritable Bowel Syndrome with Diarrhea. <i>American Journal of Gastroenterology</i> , 2011, 106, S496.	0.2	0
178	Evaluation of Rifaximin Efficacy in Non C-IBS Patients by Baseline Disease Severity: Subanalysis of the TARGET 1 and TARGET 2 Studies. <i>American Journal of Gastroenterology</i> , 2011, 106, S505-S506.	0.2	0
179	Antibiotics for the treatment of irritable bowel syndrome. <i>Gastroenterology and Hepatology</i> , 2011, 7, 455-93.	0.2	23
180	Irritable Bowel Syndrome and Small Intestinal Bacterial Overgrowth. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 672-675.	1.1	35

#	ARTICLE	IF	CITATIONS
181	A Combination of Rifaximin and Neomycin Is Most Effective in Treating Irritable Bowel Syndrome Patients With Methane on Lactulose Breath Test. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 547-550.	1.1	79
182	New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy. <i>Digestive Diseases and Sciences</i> , 2010, 55, 145-149.	1.1	30
183	Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS. <i>Digestive Diseases and Sciences</i> , 2010, 55, 398-403.	1.1	74
184	Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1085-1089.	1.1	34
185	Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2302-2308.	1.1	30
186	Methane and the Gastrointestinal Tract. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2135-2143.	1.1	185
187	Abnormal Breath Testing in IBS: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2441-2449.	1.1	140
188	Esophageal Motor Dysfunction and Gastroesophageal Reflux Are Prevalent in Lung Transplant Candidates. <i>Annals of Thoracic Surgery</i> , 2010, 90, 1630-1636.	0.7	42
189	Gender distribution in irritable bowel syndrome is proportional to the severity of constipation relative to diarrhea. <i>Gender Medicine</i> , 2010, 7, 240-246.	1.4	29
190	The Responsiveness and Validity of a Binary Weekly Recall Question and the Proposed FDA Composite Endpoint as Measures of Daily Symptom Severity in Non-Constipation Irritable Bowel Syndrome: Results of TARGET 1 and TARGET 2. <i>American Journal of Gastroenterology</i> , 2010, 105, S494.	0.2	0
191	Rifaximin Treatment Consistently Demonstrated Relief Across Daily Symptoms in Patients with Non-Constipation Irritable Bowel Syndrome: Results from 2 Phase 3 Trials (TARGET 1 and TARGET 2). <i>American Journal of Gastroenterology</i> , 2010, 105, S483-S484.	0.2	0
192	Increased Risk for ICE Among Those with IBS. <i>American Journal of Gastroenterology</i> , 2010, 105, S494.	0.2	0
193	Evaluating a Bacterial Hypothesis in IBS Using a Modification of Koch's Postulates: Part 1. <i>American Journal of Gastroenterology</i> , 2010, 105, 718-721.	0.2	29
194	Lactose Intolerance and the Role of the Lactose Breath Test. <i>American Journal of Gastroenterology</i> , 2010, 105, 1726-1728.	0.2	58
195	An Evidence-Based Treatment Algorithm for IBS Based on a Bacterial/SIBO Hypothesis: Part 2. <i>American Journal of Gastroenterology</i> , 2010, 105, 1227-1230.	0.2	15
196	T2085 Methane on Breath Testing is Associated With Constipation: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2010, 138, S-629.	0.6	2
197	475i Rifaximin Treatment for 2 Weeks Provides Acute and Sustained Relief Over 12 Weeks of IBS Symptoms in Non-Constipated Irritable Bowel Syndrome: Results From 2 North American Phase 3 Trials (Target 1 and Target 2). <i>Gastroenterology</i> , 2010, 138, S-64-S-65.	0.6	7
198	ICC density predicts bacterial overgrowth in a rat model of post-infectious IBS. <i>World Journal of Gastroenterology</i> , 2010, 16, 3680.	1.4	38

#	ARTICLE	IF	CITATIONS
199	The Methanobrevibacter smithii Concentration in Stool of Subjects with Constipation Predominant IBS is Directly Correlated with Methane on Lactulose Breath Test. American Journal of Gastroenterology, 2010, 105, S500.	0.2	0
200	Increased Risk of IBD Among Military Personnel with IBS. American Journal of Gastroenterology, 2010, 105, S460.	0.2	1
201	Defining Normal Bowel Function Relative to GI Disease: A Systematic Review of the Literature. American Journal of Gastroenterology, 2010, 105, S501.	0.2	0
202	The Treatment of Patients With Irritable Bowel Syndrome: Review of the Latest Data From the 2010 DDW Meeting. Gastroenterology and Hepatology, 2010, 6, 1-15.	0.2	1
203	Review of rifaximin as treatment for SIBO and IBS. Expert Opinion on Investigational Drugs, 2009, 18, 349-358.	1.9	84
204	A High-resolution View of Achalasia. Journal of Clinical Gastroenterology, 2009, 43, 644-651.	1.1	13
205	Proton Pump Inhibitors Do Not Affect the Lactulose Hydrogen Breath Test in IBS Subjects. American Journal of Gastroenterology, 2009, 104, S495.	0.2	1
206	Validation of a Simple Tool (Constipation Minus Diarrhea) for Evaluating Constipation Symptom Outcomes in IBS. American Journal of Gastroenterology, 2009, 104, S495-S496.	0.2	0
207	Incontinence and Anal Sphincter Pressure Predicts Rectal Sensitivity During High Resolution Anorectal Manometry. American Journal of Gastroenterology, 2009, 104, S485.	0.2	0
208	New Onset Gastroesophageal Reflux Disease After Acute Gastroenteritis: A Case of Post-Infectious GERD?. American Journal of Gastroenterology, 2009, 104, S367.	0.2	0
209	Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterology and Hepatology, 2009, 5, 435-42.	0.2	12
210	A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences, 2008, 53, 1443-1454.	1.1	248
211	Rifaximin versus Other Antibiotics in the Primary Treatment and Retreatment of Bacterial Overgrowth in IBS. Digestive Diseases and Sciences, 2008, 53, 169-174.	1.1	117
212	A New Rat Model Links Two Contemporary Theories in Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2008, 53, 982-989.	1.1	76
213	T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response. Gastroenterology, 2008, 134, A-545.	0.6	56
214	Severity of Irritable Bowel Syndrome-Related Symptoms Predicts Clinical Response to the Nonsystemic Antibiotic Rifaximin. American Journal of Gastroenterology, 2008, 103, S463.	0.2	0
215	Evaluating Breath Methane as a Diagnostic Test for Constipation Predominant IBS. American Journal of Gastroenterology, 2008, 103, S458.	0.2	0
216	Identification of Rumination with Impedance Manometry and High-Resolution Manometry. American Journal of Gastroenterology, 2008, 103, S29.	0.2	1

#	ARTICLE	IF	CITATIONS
217	A Combination of Rifaximin and Neomycin Is Most Effective in Treating Patients with Methane on Lactulose Breath Test. <i>American Journal of Gastroenterology</i> , 2008, 103, S465-S466.	0.2	0
218	The Degree of Breath Methane Production in IBS Correlates With the Severity of Constipation. <i>American Journal of Gastroenterology</i> , 2007, 102, 837-841.	0.2	181
219	A Systematic Review of Diagnostic Testing for Small Intestinal Bacterial Overgrowth. <i>American Journal of Gastroenterology</i> , 2007, 102, S202.	0.2	0
220	Nightly Tegaserod Prevents the Clinical Recurrence of Bacterial Overgrowth Symptoms. <i>American Journal of Gastroenterology</i> , 2007, 102, S499.	0.2	0
221	Irritable bowel syndrome: Bacterial overgrowth—What's known and what to do. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 328-337.	0.3	29
222	Methane Production in IBS Subjects Is Associated with a Constellation of Symptoms: Not Just Constipation. <i>American Journal of Gastroenterology</i> , 2007, 102, S499-S500.	0.2	0
223	The Efficacy of the GLP-1 Agonist Exenatide in the Treatment of Short Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2007, 102, S201-S202.	0.2	1
224	Irritable bowel syndrome: Bacterial overgrowth—What's known and what to do. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007, 10, 328-337.	0.4	0
225	Case studies of antibiotic therapy in the management of functional gastrointestinal disorders. <i>Gastroenterology and Hepatology</i> , 2007, 3, 1-12.	0.2	0
226	The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome. <i>Annals of Internal Medicine</i> , 2006, 145, 557.	2.0	417
227	Neomycin Improves Constipation-Predominant Irritable Bowel Syndrome in a Fashion That Is Dependent on the Presence of Methane Gas: Subanalysis of a Double-Blind Randomized Controlled Study. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1297-1301.	1.1	137
228	Studying the Overlap Between IBS and GERD: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2113-2120.	1.1	88
229	Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth. <i>Current Gastroenterology Reports</i> , 2006, 8, 305-311.	1.1	53
230	Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G1089-G1095.	1.6	361
231	Gastrointestinal Infection with <i>Campylobacter jejuni</i> 81/176 Produces Altered Bowel Function and Bacterial Overgrowth in Rats. <i>American Journal of Gastroenterology</i> , 2006, 101, S472.	0.2	3
232	High-Resolution Manometry Anorectal Manometry. <i>American Journal of Gastroenterology</i> , 2006, 101, S218.	0.2	0
233	Rifaximin Is Superior to Other Antibiotics in Treating and Retreating Bacterial Overgrowth in IBS, Supporting a Lack of Bacterial Resistance Development. <i>American Journal of Gastroenterology</i> , 2006, 101, S475.	0.2	0
234	In the Treatment of IBS, the Clinical Response to Rifaximin Is Determined by the Normalization of the Lactulose Breath Test. <i>American Journal of Gastroenterology</i> , 2006, 101, S474-S475.	0.2	0

#	ARTICLE	IF	CITATIONS
235	Measurement of Gastrointestinal Transit. <i>Digestive Diseases and Sciences</i> , 2005, 50, 989-1004.	1.1	153
236	Rifaximin, a Non-Absorbable Antibiotic, Improves the Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2005, 100, S324.	0.2	15
237	Significant Overlap between IBS and GERD. <i>American Journal of Gastroenterology</i> , 2005, 100, S324.	0.2	1
238	Bacterial concepts in irritable bowel syndrome. <i>Reviews in Gastroenterological Disorders</i> , 2005, 5 Suppl 3, S3-9.	0.6	6
239	A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 450-452.	0.5	124
240	A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test. <i>Digestive Diseases and Sciences</i> , 2004, 49, 73-77.	1.1	73
241	IBS Subjects with Methane on Lactulose Breath Test Have Lower Postprandial Serotonin Levels Than Subjects with Hydrogen. <i>Digestive Diseases and Sciences</i> , 2004, 49, 84-87.	1.1	51
242	Methane production during lactulose breath test is associated with gastrointestinal disease presentation. <i>Digestive Diseases and Sciences</i> , 2003, 48, 86-92.	1.1	216
243	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2003, 98, 412-419.	0.2	11
244	Response to Dr. Parisi et al.. <i>American Journal of Gastroenterology</i> , 2003, 98, 2573-2574.	0.2	3
245	Breath Testing To Evaluate Lactose Intolerance in Irritable Bowel Syndrome Correlates With Lactulose Testing and May Not Reflect True Lactose Malabsorption. <i>American Journal of Gastroenterology</i> , 2003, 98, 2700-2704.	0.2	64
246	Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , 2003, 98, 412-419.	0.2	586
247	THE PRESENCE OF CONSTIPATION AND METHANE ON LACTULOSE BREATH TEST IN IBS SUBJECTS IS ASSOCIATED WITH LOWER SEROTONIN LEVELS COMPARED TO HYDROGEN ALONE. <i>American Journal of Gastroenterology</i> , 2003, 98, S72.	0.2	69
248	Do antibiotics influence IBS?. <i>American Journal of Gastroenterology</i> , 2002, 97, 2681-2681.	0.2	5
249	Increased Prevalence of Irritable Bowel Syndrome in Patients With Gastroesophageal Reflux. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 221-224.	1.1	64
250	Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. <i>Digestive Diseases and Sciences</i> , 2002, 47, 2639-2643.	1.1	136
251	Peppermint Oil Improves the Manometric Findings in Diffuse Esophageal Spasm. <i>Journal of Clinical Gastroenterology</i> , 2001, 33, 27-31.	1.1	75
252	Postprandial improvement of gastric dysrhythmias in patients with type II diabetes: identification of responders and nonresponders. <i>Digestive Diseases and Sciences</i> , 2001, 46, 705-712.	1.1	17

#	ARTICLE	IF	CITATIONS
253	Evidence- and Consensus-Based Practice Guidelines for the Diagnosis of Irritable Bowel Syndrome. Archives of Internal Medicine, 2001, 161, 2081.	4.3	65
254	Response to Dr. Riordan et al.. American Journal of Gastroenterology, 2001, 96, 2507-2508.	0.2	1
255	Response to Drs. Mishkin. American Journal of Gastroenterology, 2001, 96, 2505-2506.	0.2	0
256	Small Intestinal Bacterial Overgrowth: A Possible Association with Fibromyalgia. Journal of Musculoskeletal Pain, 2001, 9, 105-113.	0.3	18
257	Identification of A Prodromal Period in Crohn's Disease But Not Ulcerative Colitis. American Journal of Gastroenterology, 2000, 95, 3458-3462.	0.2	124
258	Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2000, 95, 3503-3506.	0.2	649
259	Aberrant TGF- $\beta$ 2 Production and Regulation in Metastatic Malignancy. Growth Factors, 1990, 3, 115-127.	0.5	62
260	Intestinal Methanobrevibacter smithii but Not Total Bacteria Is Related to Diet-Induced Weight Gain in Rats. Obesity, 0, , .	1.5	2
261	The Response of the Rodent Gut Microbiome to Broad-Spectrum Antibiotics Is Different in Males and Females. Frontiers in Microbiology, 0, 13, .	1.5	2